New HIV Vaccine Tested In USA

23 April 1995

Cel-Sci Corp of Virginia and Alpha-1 Biomedicals Inc of Maryland in the USA have commenced a clinical study of HGP-30, a potential vaccine for HIV infection. 15 healthy subjects, who took part in a safety study of HGP-30 three to four years ago, will participate in the new study, according to the two firms.

The vaccine has already been tested in two clinical trials with HIV-negative volunteers in California and the UK. Viral Technologies, a joint venture of Cel-Sci and Alpha 1, owns all rights to HGP-30.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight